ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders
January 15 2019 - 6:25PM
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical
company focused on the development and commercialization of
therapeutic drugs for the treatment of liver disease arising from
chronic viral infection and non-alcoholic steatohepatitis,
announced today that its 2018 Annual Meeting of Stockholders
scheduled to be held on January 15, 2019 (the “Annual Meeting”) was
adjourned due to a lack of a quorum on the proposals to be
approved. The Company intends to set a new record date and will add
additional proposals to be voted on at the Annual Meeting.
The Company will file and mail a new proxy statement to its
shareholders of record as soon as practical after its Board of
Directors approves the new record date and schedules a new date and
time for its Annual Meeting.
About ContraVir Pharmaceuticals ContraVir is a
biopharmaceutical company focused on the development and
commercialization of targeted therapies for liver disease arising
from chronic hepatitis B, C and D virus (HBV, HVC, HDV) and
non-alcoholic steatohepatitis (NASH). The company is developing two
novel anti-HBV compounds with complementary mechanisms of action.
TXL™, a direct acting antiviral (DAA) nucleotide analog lipid
prodrug of tenofovir (TFV), is designed to deliver higher hepatic
intracellular concentrations of the active tenofovir species
(tenofovir diphosphate) while reducing concentrations of tenofovir
outside the liver, causing fewer off-target toxicities and
side-effects. CRV431, the other anti-HBV compound, is a
host-targeting antiviral (HTA) next-generation cyclophilin
inhibitor with a novel chemical structure that optimizes the
selective index against HBV. In vitro and in
vivo studies have thus far demonstrated that CRV431 reduces
HBV DNA and other viral proteins, including surface antigen
(HBsAg), while offering additional benefits such as reducing liver
fibrosis and hepatocellular carcinoma tumor burden. For more
information visit www.contravir.com
Forward Looking Statements Certain statements
in this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimated" and "intend,"
among others. These forward-looking statements are based on
ContraVir's current expectations and actual results could differ
materially. There are a number of factors that could cause actual
events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to, substantial competition; our ability to continue as a
going concern; our need for additional financing; uncertainties of
patent protection and litigation; uncertainties with respect to
lengthy and expensive clinical trials, that results of earlier
studies and trials may not be predictive of future trial results;
uncertainties of government or third party payer reimbursement;
limited sales and marketing efforts and dependence upon third
parties; and risks related to failure to obtain FDA clearances or
approvals and noncompliance with FDA regulations. As with any drug
candidates under development, there are significant risks in the
development, regulatory approval, and commercialization of new
products. There are no guarantees that future clinical trials
discussed in this press release will be completed or successful, or
that any product will receive regulatory approval for any
indication or prove to be commercially successful. ContraVir does
not undertake an obligation to update or revise any forward-looking
statement. Investors should read the risk factors set forth in
ContraVir's Form 10-KT for the year ended December 30, 2017 and
other periodic reports filed with the Securities and Exchange
Commission.
For further information, please contact:
Stephen Kilmer ContraVir Investor Relations(646)
274-3580skilmer@contravir.com
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Apr 2023 to Apr 2024